Circular RNA ATP2C1 (has_circ_0005797) sponges miR-432/miR-335 to promote breast cancer progression through regulating CCND1 expression

被引:0
作者
Chen, Caiping [1 ]
Lu, Jianju [1 ]
Li, Wang [1 ,2 ]
Lu, Xiang [1 ]
机构
[1] Jiaxing Univ, Affiliated Hosp, Hosp Jiaxing 1, Dept Breast Surg, Jiaxing, Zhejiang, Peoples R China
[2] Bengbu Med Coll, Sch Grad, Bengbu, Anhui, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 08期
关键词
Breast cancer; ceRNA; circATP2C1; miR-432/miR-335; CCND1; MIRNA-MESSENGER-RNA; PROLIFERATION; METASTASIS; STATISTICS; CELLS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer (BC) is the most frequently diagnosed malignancy in the world. Accumulating evidence has indicated that circular RNAs (circRNAs) play essential roles in BC. Here we investigated the biological functions of circATP2C as a competing endogenous RNA (ceRNA) in BC development. We found that circATP2C1 expression was upregulated in BC cells and tissues and was significantly associated with the poor overall survival in BC patients. CircATP2C1 is more resistant to RNase R exonuclease and Actinomycin D than is the linear mRNA of ATP2C1. CircATP2C1-knockdown inhibited the viability, colony proliferation and invasion abilities, while increasing the apoptosis rates of BC cells in vitro, as well as inhibiting tumor mass, size and weight in vivo. Upregulation of miR-432 and miR-335 inhibited CCND1 expression in BC cells. Both miR-432/miR-335 specifically bind to the 3'-UTR of circATP2C1 and CCND1 (CyclinD1). The inhibition of the aggression of BC cells by circATP2C1-knockdown was rescued by co-transfection of miR-432/miR-335 inhibitors. In conclusion, circATP2C1 promotes BC oncogenesis and metastasis by sponging miR-432/miR-335 to abolish the inhibition of the target gene, CCND1. This study suggests that circATP2C1 has implications for BC diagnosis and treatment.
引用
收藏
页码:3433 / 3448
页数:16
相关论文
共 51 条
[11]   Circular RNA and its mechanisms in disease: From the bench to the clinic [J].
Han, Bing ;
Chao, Jie ;
Yao, Honghong .
PHARMACOLOGY & THERAPEUTICS, 2018, 187 :31-44
[12]   miRNA interplay: mechanisms and consequences in cancer [J].
Hill, Meredith ;
Tran, Nham .
DISEASE MODELS & MECHANISMS, 2021, 14 (04)
[13]   A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer [J].
Huang, Peide ;
Li, Fengyu ;
Mo, Zongchao ;
Geng, Chunyu ;
Wen, Fang ;
Zhang, Chunyan ;
Guo, Jia ;
Wu, Song ;
Li, Lin ;
Brunner, Nils ;
Stenvang, Jan .
FRONTIERS IN ONCOLOGY, 2021, 11
[14]   CircRNA DDX21 acts as a prognostic factor and sponge of miR-1264/QKI axis to weaken the progression of triple-negative breast cancer [J].
Huang, Renhong ;
Yang, Zhou ;
Liu, Qian ;
Liu, Biao ;
Ding, Xinyuan ;
Wang, Zheng .
CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05)
[15]   Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis [J].
Jia, Qianxin ;
Ye, Lanlan ;
Xu, Shangwen ;
Xiao, Hui ;
Xu, Siding ;
Shi, Zhaoyin ;
Li, Jinsheng ;
Chen, Ziqian .
THORACIC CANCER, 2020, 11 (03) :619-630
[16]  
Jin LT, 2021, AGING-US, V13, P19306, DOI 10.18632/aging.203272
[17]   Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis [J].
Kumar, Vinod ;
Kumar, Virender ;
Chaudhary, Amit Kumar ;
Coulter, Donald W. ;
McGuire, Timothy ;
Mahato, Ram, I .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2018, 12 :490-503
[18]   DRAIC promotes growth of breast cancer by sponging miR-432-5p to upregulate SLBP [J].
Li, Sijie ;
Jia, Hongyao ;
Zhang, Zhiru ;
Wu, Di .
CANCER GENE THERAPY, 2022, 29 (07) :951-960
[19]   MicroRNA-374b inhibits breast cancer progression through regulating CCND1 and TGFA genes [J].
Liu, Yan ;
Zhang, Ai ;
Bao, Ping-Ping ;
Lin, Li ;
Wang, Yina ;
Wu, Haijian ;
Shu, Xiao-Ou ;
Liu, Aiguo ;
Cai, Qiuyin .
CARCINOGENESIS, 2021, 42 (04) :528-536
[20]   Circular RNA hsa_circ_0008039 promotes breast cancer cell proliferation and migration by regulating miR-432-5p/E2F3 axis [J].
Liu, Yanhua ;
Lu, Cuntao ;
Zhou, Yizhou ;
Zhang, Zhihong ;
Sun, Li .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 502 (03) :358-363